Lung Cancer | Specialty

Pemetrexed for Advanced NSCLC

June 25th 2019

Antiangiogenic Therapy in Advanced NSCLC

June 25th 2019

The KEYNOTE-407 Trial in Metastatic Squamous NSCLC

June 25th 2019

Approaching Non-Driver Stage IV NSCLC

June 25th 2019

Immunotherapy in Early Stage NSCLC

June 25th 2019

Immunotherapy in Stage III NSCLC

June 25th 2019

Reactions to the PACIFIC Trial in Stage III NSCLC

June 25th 2019

Locally Advanced NSCLC and Treatment Decisions

June 25th 2019

Locally Advanced NSCLC: Staging and Diagnosis

June 25th 2019

Combined Modality Approach May Benefit Select Patients With Oligometastatic NSCLC

June 25th 2019

Daniel Gomez, MD, provides insight on the different treatment approaches under exploration for patients with oligometastatic disease.

Expert Carefully Considers New Immunotherapy Combos in Nonsquamous NSCLC

June 23rd 2019

Jared Weiss, MD, discusses key trials in nonsquamous non–small cell lung cancer in depth and their impact on the field.

Dr. Antonia on Investigational Immunotherapy Combinations in Stage III NSCLC

June 21st 2019

Scott J. Antonia, MD, PhD, instructor, Duke University School of Medicine, member, Duke Cancer Institute, discusses investigational immunotherapy combinations in stage III non–small cell lung cancer (NSCLC).

Dr. Langer on the Current State of Immunotherapy in Advanced NSCLC

June 20th 2019

Corey J. Langer, MD, director, Thoracic Oncology, Abramson Cancer Center, professor of medicine, Perelman School of Medicine, University of Pennsylvania, discusses the current state of immunotherapy in advanced non–small cell lung cancer.

Dr. Sands on the Rationale to Explore DS-1062 in Advanced NSCLC

June 20th 2019

Jacob Sands, MD, physician, Dana-Farber Cancer Institute, instructor in medicine, Harvard Medical School, discusses the rationale to explore DS-1062 in advanced non–small cell lung cancer (NSCLC).

Dr. Gainor on Potential With BLU-667 in RET+ NSCLC

June 20th 2019

Justin F. Gainor, MD, director of targeted immunotherapy, Massachusetts General Hospital, assistant professor of medicine, Harvard Medical School, discusses clinical activity and tolerability of BLU-667 in patients with advanced RET-fusion+ non-small cell lung cancer (NSCLC).

Dr. Pecot on the Frontline Standard of Care in Squamous NSCLC

June 20th 2019

Chad Pecot, MD, assistant professor, Department of Medicine, University of North Carolina (UNC) Lineberger Comprehensive Cancer Center, discusses the frontline standard of care in advanced squamous non–small cell lung cancer (NSCLC).

Quest Continues to Turn NSCLC Into Chronic Disease

June 20th 2019

Nirav S. Dhruva, MD, highlightes key advances made in non–small cell lung cancer, the importance of PD-L1 expression testing, and ongoing efforts to bridge the gap between community and academic centers in lung cancer care.

PACIFIC Study Sets New Standard in Stage III NSCLC, Opens Door to Further Progress

June 19th 2019

Scott J. Antonia, MD, PhD, discusses the pivotal data that renewed interest in stage III unresectable non–small cell lung cancer and anticipated data that are expected to advance the field even further.

Dr. Nagawaka Discusses Findings of the RELAY Trial in EGFR+ NSCLC

June 19th 2019

Kazuhiko Nakagawa, MD, PhD, Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka-Sayama, Osaka, Japan, discusses findings of the RELAY trial in EGFR-positive non–small cell lung cancer.

Dr. Gadgeel on Updated KEYNOTE-189 Data in NSCLC

June 18th 2019

Shirish M. Gadgeel, MD, MBBS, professor, University of Michigan Medicine, discusses the updated results of the phase III KEYNOTE-189 trial in metastatic nonsquamous non-small cell lung cancer (NSCLC).